Cerus Corporation (NASDAQ:CERS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET

Company Participants

Matt Notarianni – Senior Director-Investor Relations

Obi Greenman – President and Chief Executive Officer

Vivek Jayaraman – Chief Operating Officer

Kevin Green – Chief Financial Officer

Conference Call Participants

Brandon Folkes – Cantor Fitzgerald

Eric Anderson – Cowen

Operator

Good day, ladies and gentlemen. Thank you for standing by. And welcome to the Cerus Corporation First Quarter 2022 Earnings Conference Call. At this time all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker host today, Mr. Matt Notarianni, Senior Director of Investor Relations. Mr. Notarianni, you may begin

Matt Notarianni

Thank you, and good afternoon. I'd like to thank everyone for joining us today.

As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.cerus.com.

With me on the call are Obi Greenman, Cerus' President and Chief Executive Officer; Kevin Green, Cerus' Chief Financial Officer; Vivek Jayaraman, Cerus' Chief Operating Officer; Carol Moore, Cerus' Senior Vice President of Regulatory Affairs and Quality; and Jessica Hanover, Cerus' Vice President of Corporate Affairs.

Cerus issued a press release today announcing our financial results for the first quarter ended March 31, 2022 and describing the Company's recent business highlights. You can access a copy of this announcement on the Company website at www.cerus.com.

I'd like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts, and are forward-looking statements. Examples of forward-looking statements include those related to our future financial and operating results, including our 2022 product revenue guidance and goals, operating expenses, anticipated cash use from operations, gross profits and gross margins, as well as commercial development efforts, future growth and growth strategy, future product sales, product launches, ongoing and future clinical trials, ongoing and future product development and our regulatory initiatives, including the timing of these events and activities.

These forward-looking statements involve risks and uncertainties that can cause actual events, performance, and results to differ materially. They are identified and described in today's press release and under Risk Factors in our Form 10-K for the year ended December 31, 2021, and our Form 10-Q for the quarter ended March 31, 2022 which we will file shortly. We undertake no duty or obligation to update our forward-looking statements.